2023-06-06 22:30:36
In recent days, the impressive story of Paulo Peregrinoa cancer patient who underwent an innovative treatment against this disease and has managed to eliminate the tumors that he had in his body in just one month.
According to the American media CNN, the patient of brazilian nationality arrived at the doctor’s office with a very developed disease that produced a series of tumors throughout the body.
(It may be of interest to you: A pill manages to stop the advance of a malignant brain tumor for several years).
Despite the seriousness of the patient, the doctors decided to subject him to intensive treatment with modified cells (CAR-T), that in just 30 days, managed to remove all tumors that Paulo Peregrino had before arriving at the hospital.
Related topics
This is a treatment that involves genetically modifying the body’s immune cells, reduces the risk of progression by 74% of the disease in people with a rare type of blood cancer, according to study results published Monday.
The most incredible thing about Peregrino’s case was that underwent 5 years of chemotherapy, but it never achieved the results that the treatment with the cells (CAR-T) had in only one month of treatment.
The 61-year-old patient began the process with these modified cells on March 23 of this year, after taking an X-ray, which showed the different tumors he had in his body. On April 24 he underwent another x-ray and showed the ‘scientific miracle’, I didn’t have a single tumor.
“Little by little I am thinking about the fact that that really is a miracle of science”, expressed Paulo Peregrino to CNN.
Cell treatment details (CAR-T)
The ‘ciltacabtagén autoleucel’, also known by its trade name as Tsarvykti was tested in a clinical trial involving 419 patients with multiple myeloma unresponsive to commonly indicated chemotherapy treatment with lenalidomide.
offers remarkably effective results compared to current patient options
While the latter’s use “has become more widespread, so has the number of patients whose disease is no longer responsive to treatment,” oncologist Oreofe Odejide said at the annual meeting of the American Society for Medical Oncology, where the results.
Carvykti “offers remarkably effective results compared to current patient options” and “can be used safely at an earlier stage of treatment,” added Odejide, who was not involved in this study.
In the clinical trial, half of the patients received Carvykti and the other half received a cocktail of currently commonly prescribed drugs, including chemotherapy and steroids. “After a median follow-up of 16 months, the investigators found that ciltacabtagen autoleucel reduced the risk of disease progression by 74% compared to standard treatments,” a statement said.
Multiple myeloma is a blood cancer that affects a type of white blood cells called plasma cells or plasma cells. and can cause gradual damage in the bones, kidneys and the immune system. It affects seven out of every 100,000 people each year, according to the Cleveland Clinic.
The risk increases with age, and has higher incidence in men and black people. Currently, there is no cure, although its progress can be delayed or stopped for a long time.
(Read here: Liver cancer: seven healthy habits to prevent its appearance).
The new treatment involves removing the patient’s chimeric antigen receptor (CAR) T cells and genetically modify them in a laboratory so that they have specific proteins called receptors that can seek out and kill cancer cells.
During the clinical trial, the number of serious or life-threatening adverse events was slightly higher in the group receiving
Carvykti than in the other (97% vs. 94%). In addition, three quarters of the participants suffered an excessive immune reaction and approximately 5%, a neurotoxicity syndrome.
Researchers will continue to follow all of these patients to determine the long-term effects and impact on quality of life of these treatments. The clinical trial was funded by Janssen Research & Development and Legend Biotech USA.
More news in EL TIEMPO
1686098885
#cancer #patient #cured #tumors #innovative #treatment